Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m). Asahi Kasei plans to use its infrastructure and R&D to accelerate the development and commercialisation of Aicuris’s robust pipeline.
The acquisition will expand the company’s speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary closing conditions. The company anticipates the deal to positively impact operating income from fiscal 2028 onwards, after the amortisation of goodwill and intangible assets.
Strategic Alignment and Synergies
According to Asahi Kasei, this strategic move is closely aligned with its ongoing initiative to develop a focused and sustainable speciality pharma platform designed specifically for immunocompromised and medically complex patients.
Severe infectious diseases are considered strategically adjacent to Asahi Kasei’s existing core transplant (Veloxis) and nephrology (Calliditas) subsidiaries. Infection-related complications are a significant concern and frequent challenge within these critical medical sectors.
Asahi Kasei intends to use its established commercial infrastructure in transplant centres and nephrology providers, along with its advanced research and development (R&D) capabilities, to expedite the commercialisation and clinical development of Aicuris’ targeted pipeline.
Enhancing the Pipeline and Financial Outlook
Added Pipeline Assets
Aicuris adds three key compounds to Asahi Kasei’s portfolio:
- Prevymis (letermovir): Providing immediate royalty earnings.
- Pritelivir: Holding potential for commercial success, with approval expected in fiscal year 2026.
- AIC468: Offering significant long-term therapeutic potential.
The portfolio significantly boosts Asahi Kasei’s financial outlook by integrating immediate royalty earnings from Prevymis with the near-term commercial potential of pritelivir. Alongside the long-term potential of AIC468, the acquisition provides a multi-tiered growth strategy that enhances revenue stability for the corporation.
Corporate Restructuring Efforts
Asahi Kasei continues restructuring its business towards high-growth opportunities through such strategic investments under its management plan, “Trailblaze Together”. This approach builds on previous strategic moves; for example, in May 2024, Asahi Kasei made a public cash offer for the acquisition of all shares in Swedish drugmaker Calliditas for Skr11.16bn ($1.04bn).
